Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

Meier JJ.

Nat Rev Endocrinol. 2012 Dec;8(12):728-42. doi: 10.1038/nrendo.2012.140. Epub 2012 Sep 4. Review.

PMID:
22945360
2.

The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.

Guo XH.

Curr Med Res Opin. 2016;32(1):61-76. doi: 10.1185/03007995.2015.1103214. Epub 2015 Nov 11. Review.

PMID:
26439329
3.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A.

Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Review.

PMID:
22232377
4.

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.

Owens DR, Monnier L, Bolli GB.

Diabetes Metab. 2013 Dec;39(6):485-96. doi: 10.1016/j.diabet.2013.09.004. Epub 2013 Oct 22. Review.

PMID:
24156868
5.

GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.

Triplitt C, Solis-Herrera C.

Diabetes Educ. 2015 Dec;41(1 Suppl):32S-46S. doi: 10.1177/0145721715607981. Epub 2015 Oct 8. Review.

PMID:
26450217
6.

GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

Derosa G, Maffioli P.

Curr Clin Pharmacol. 2012 Aug;7(3):214-28. Review.

PMID:
22432846
7.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
8.

GLP-1 based therapies: differential effects on fasting and postprandial glucose.

Fineman MS, Cirincione BB, Maggs D, Diamant M.

Diabetes Obes Metab. 2012 Aug;14(8):675-88. doi: 10.1111/j.1463-1326.2012.01560.x. Epub 2012 Feb 13. Review.

PMID:
22233527
9.

[Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].

Camafort-Babkowski M.

Med Clin (Barc). 2013 Aug 17;141(4):167-74. doi: 10.1016/j.medcli.2012.11.016. Epub 2013 Jan 18. Review. Spanish.

PMID:
23332622
10.

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.

Gallwitz B.

Drugs. 2011 Sep 10;71(13):1675-88. doi: 10.2165/11592810-000000000-00000. Review.

PMID:
21902291
11.
12.

Emerging GLP-1 receptor agonists.

Lund A, Knop FK, Vilsbøll T.

Expert Opin Emerg Drugs. 2011 Dec;16(4):607-18. doi: 10.1517/14728214.2011.616493. Epub 2011 Sep 9. Review.

PMID:
21905764
13.

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.

Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Review.

PMID:
21208359
14.

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.

Madsbad S.

Diabetes Obes Metab. 2016 Apr;18(4):317-32. doi: 10.1111/dom.12596. Epub 2015 Dec 29. Review.

15.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Review.

PMID:
22471248
16.

Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.

González C, Beruto V, Keller G, Santoro S, Di Girolamo G.

Expert Opin Investig Drugs. 2006 Aug;15(8):887-95. Review.

PMID:
16859392
17.

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.

Østergaard L, Frandsen CS, Madsbad S.

Expert Rev Clin Pharmacol. 2016;9(2):241-65. doi: 10.1586/17512433.2016.1121808. Epub 2016 Jan 8. Review.

PMID:
26573176
18.

A Plethora of GLP-1 Agonists: Decisions About What to Use and When.

Samson SL, Garber AJ.

Curr Diab Rep. 2016 Dec;16(12):120. Review.

PMID:
27766579
19.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
20.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group.

Lancet. 2009 Jul 4;374(9683):39-47. doi: 10.1016/S0140-6736(09)60659-0. Epub 2009 Jun 8.

PMID:
19515413

Supplemental Content

Support Center